Does total lesion prostate-specific membrane antigen (PSMA) activity on 68Ga-PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?

IF 1.6 Q3 UROLOGY & NEPHROLOGY
BJUI compass Pub Date : 2025-04-16 DOI:10.1002/bco2.70015
Jeremy Cheng, Mohammadmehdi Adhami, Tho Pham, David P. Nadebaum, Ashley Baring, Eldho Paul, Martin Cherk, Jeremy Grummet
{"title":"Does total lesion prostate-specific membrane antigen (PSMA) activity on 68Ga-PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?","authors":"Jeremy Cheng,&nbsp;Mohammadmehdi Adhami,&nbsp;Tho Pham,&nbsp;David P. Nadebaum,&nbsp;Ashley Baring,&nbsp;Eldho Paul,&nbsp;Martin Cherk,&nbsp;Jeremy Grummet","doi":"10.1002/bco2.70015","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To evaluate the relationship between total lesion PSMA (PSMA<sub>TL</sub>), serum PSA, histopathological findings and biochemical recurrence (BCR) in patients with localised prostate cancer (PCa).</p>\n </section>\n \n <section>\n \n <h3> Patients and methods</h3>\n \n <p>This retrospective study assessed men undergoing <sup>68</sup>Ga-PSMA-11 PET/CT for newly diagnosed or treatment-naïve PCa localised to the prostate gland. Volumes of interest were manually mapped to derive SUV<sub>max</sub>, SUV<sub>mean</sub>, PSMA-avid tumour volume and PSMA<sub>TL</sub>. PSMA<sub>TL</sub> was defined as the product of PSMA-avid primary tumour volume and SUV<sub>mean</sub>. Spearman correlation tests evaluated associations between PET parameters and PSA, ISUP GG and radical prostatectomy (RP) histopathological outcomes. Associations between PET parameters and clinical outcomes were determined using Cox proportional hazards regression with results presented as HR and 95% CI.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 200 patients were included, with a median age of 68 (IQR 62–73) years, PSA of 9.5 (6.6–13.0) ng/ml and follow-up of 41 (25–60) months. Median PSMA<sub>TL</sub> was 29.6 (14.8–54.8) and SUV<sub>max</sub> 11.0 (6.8–17.9). PSMA<sub>TL</sub> and SUV<sub>max</sub> demonstrated a weak correlation with baseline PSA (ρ = 0.334, p &lt; 0.001 and ρ = 0.343, p &lt; 0.001), and PSMA<sub>TL</sub> showed a weak correlation with PSA density in the RP subgroup (ρ = 0.242, p = 0.021). Among 109 (54.5%) patients undergoing RP, PSMA<sub>TL</sub> and SUV<sub>max</sub> showed a weak correlation with ISUP GG (ρ = 0.233, p = 0.015 and ρ = 0.340, p &lt; 0.001). There was a weak correlation between PSMA<sub>TL</sub> and primary tumour stage (ρ = 0.244, p = 0.010) and lymph node stage (ρ = 0.259, p = 0.007). PSMA<sub>TL</sub> was significantly higher in those with seminal vesicle involvement (p = 0.011), perineural invasion (p = 0.025) and lymphovascular invasion (p = 0.002). BCR occurred in 46 patients (42%), with a 1% increased risk of BCR per unit increase in PSMA<sub>TL</sub> (HR 1.01, 95% CI 1.00–1.02, p = 0.011).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PSMA<sub>TL</sub> correlates with PSA, PSA density, ISUP GG, RP histopathological findings and BCR. As an adjunct to SUV<sub>max</sub>, PSMA<sub>TL</sub> has the potential to be a useful prognostic tool. Further research is needed to assess its clinical utility.</p>\n </section>\n </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 4","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70015","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJUI compass","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bco2.70015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To evaluate the relationship between total lesion PSMA (PSMATL), serum PSA, histopathological findings and biochemical recurrence (BCR) in patients with localised prostate cancer (PCa).

Patients and methods

This retrospective study assessed men undergoing 68Ga-PSMA-11 PET/CT for newly diagnosed or treatment-naïve PCa localised to the prostate gland. Volumes of interest were manually mapped to derive SUVmax, SUVmean, PSMA-avid tumour volume and PSMATL. PSMATL was defined as the product of PSMA-avid primary tumour volume and SUVmean. Spearman correlation tests evaluated associations between PET parameters and PSA, ISUP GG and radical prostatectomy (RP) histopathological outcomes. Associations between PET parameters and clinical outcomes were determined using Cox proportional hazards regression with results presented as HR and 95% CI.

Results

A total of 200 patients were included, with a median age of 68 (IQR 62–73) years, PSA of 9.5 (6.6–13.0) ng/ml and follow-up of 41 (25–60) months. Median PSMATL was 29.6 (14.8–54.8) and SUVmax 11.0 (6.8–17.9). PSMATL and SUVmax demonstrated a weak correlation with baseline PSA (ρ = 0.334, p < 0.001 and ρ = 0.343, p < 0.001), and PSMATL showed a weak correlation with PSA density in the RP subgroup (ρ = 0.242, p = 0.021). Among 109 (54.5%) patients undergoing RP, PSMATL and SUVmax showed a weak correlation with ISUP GG (ρ = 0.233, p = 0.015 and ρ = 0.340, p < 0.001). There was a weak correlation between PSMATL and primary tumour stage (ρ = 0.244, p = 0.010) and lymph node stage (ρ = 0.259, p = 0.007). PSMATL was significantly higher in those with seminal vesicle involvement (p = 0.011), perineural invasion (p = 0.025) and lymphovascular invasion (p = 0.002). BCR occurred in 46 patients (42%), with a 1% increased risk of BCR per unit increase in PSMATL (HR 1.01, 95% CI 1.00–1.02, p = 0.011).

Conclusions

PSMATL correlates with PSA, PSA density, ISUP GG, RP histopathological findings and BCR. As an adjunct to SUVmax, PSMATL has the potential to be a useful prognostic tool. Further research is needed to assess its clinical utility.

在局部原发性前列腺癌患者中,68Ga-PSMA PET/CT 显示的总病灶前列腺特异性膜抗原 (PSMA) 活性与 PSA 和前列腺切除术组织病理学/临床结果是否相关?
目的探讨局限性前列腺癌(PCa)患者病变总PSMA (PSMATL)、血清PSA、组织病理学表现与生化复发(BCR)的关系。患者和方法本回顾性研究评估了接受68Ga-PSMA-11 PET/CT检查新诊断或treatment-naïve前列腺癌的男性。人工绘制感兴趣的体积,以获得SUVmax, SUVmean, PSMA-avid肿瘤体积和PSMATL。PSMATL定义为原发肿瘤体积与SUVmean的乘积。Spearman相关试验评估PET参数与PSA、ISUP GG和根治性前列腺切除术(RP)组织病理学结果之间的关系。使用Cox比例风险回归确定PET参数与临床结果之间的关联,结果以HR和95% CI表示。结果共纳入200例患者,中位年龄68 (IQR 62 ~ 73)岁,PSA 9.5 (6.6 ~ 13.0) ng/ml,随访41(25 ~ 60)个月。中位PSMATL为29.6 (14.8-54.8),SUVmax为11.0(6.8-17.9)。PSMATL和SUVmax与基线PSA呈弱相关(ρ = 0.334, p <; 0.001和ρ = 0.343, p < 0.001), PSMATL与RP亚组PSA密度呈弱相关(ρ = 0.242, p = 0.021)。在109例(54.5%)RP患者中,PSMATL和SUVmax与ISUP GG呈弱相关(ρ = 0.233, p = 0.015, ρ = 0.340, p < 0.001)。PSMATL与原发肿瘤分期(ρ = 0.244, p = 0.010)和淋巴结分期(ρ = 0.259, p = 0.007)呈弱相关。精囊受累(p = 0.011)、神经周围浸润(p = 0.025)和淋巴血管浸润(p = 0.002)患者PSMATL显著增高。46例患者(42%)发生BCR, PSMATL每单位增加BCR的风险增加1% (HR 1.01, 95% CI 1.00-1.02, p = 0.011)。结论PSMATL与PSA、PSA密度、ISUP GG、RP组织病理表现及BCR相关。作为SUVmax的辅助手段,PSMATL有可能成为一种有用的预后工具。需要进一步的研究来评估其临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信